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OBJECTIVES: To estimate the ﬁnancial impact to the Ontario
Public Drug Programs (OPDP) for providing coverage for
methylnaltrexone subcutaneous injection (RELISTORTM) for the
treatment of Opioid Induced Constipation (OIC) in patients with
advanced illness, receiving palliative care when response to laxa-
tives has been insufﬁcient. METHODS: A population-based
model was developed to estimate the annual ﬁnancial impact of
adding methylnaltrexone to the OPDP drug formulary. Attrition
factors were applied in a stepwise approach starting with the
population of Ontario in order to forecast the number of pallia-
tive patients expected to use methylnaltrexone following its addi-
tion to the drug formulary. Targeted treatment population in the
analysis is limited to patients meeting the product monograph
indication/criteria. Only drug costs incurred by the OPDP are
included. No discounting or inﬂation were applied. Data sources
included literature sources, publicly available population statis-
tics, and market research. RESULTS: This analysis estimates that
funding methylnaltrexone, per product monograph indication,
in the province of Ontario would lead to an incremental drug
reimbursement cost of $1,754,265, $3,942,857, and $5,563,842
in Year 1, 2, and 3 respectively post listing. The total cumulative
impact, post listing over the three-year period is expected to be
$11.26 million. Pessimistic and optimistic scenarios were evalu-
ated in the sensitivity analysis to provide a range of costs to the
drug plan budget. The estimated impact over a three-year period
will be an incremental cost of $6.65 million and $17.46 million
for pessimistic and optimistic scenario respectively. CONCLU-
SIONS: Addition of methylnaltrexone will provide patients and
care providers with a therapeutic option to rapidly and reliably
improve patient well-being at the end-of-life while having a
modest impact on the OPDP drug budget.
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OBJECTIVES: A budget impact model was developed in order to
estimate the economic impact of increased pantoprazole intrave-
nous prescription in themanagement of Peptic Ulcer (PU) in Spain.
METHODS: The analytic model is based on data from disease
prevalence, population growth, drug consumption, ex-factory
prices andmarket shares forecasts for the Spanish market. It takes
the perspective of the Spanish National Health Care System and
time horizon considered is 5 years (annual discount rate at 5%).
Drugs considered in the study were intravenous proton-pump
inhibitors (PPIs): omeprazole, esomeprazole and pantoprazole.
The model estimates the annual cost to treat patients with PU
before and after of increased pantoprazol IV prescription. Annual
costs includes pharmacologic treatment, laboratory and diag-
nostic tests, specialist consultation, hospitalization and other
resources like transfusions, endoscopic treatments and surgery
interventions. Health care resource consumption and unit costs
have been obtained from a retrospective observational study that
evaluated the re-bleeding prevalence by PU in patients treatedwith
intravenous PPIs. All costs are referred to year 2007. RESULTS:
Target population with peptic ulcer in Spain would be around
362,193 in year 2007, arriving at 378,048 in 2012 due to increase
in Spanish population. Of these population it has been estimated
that 5092 patients in year 2007would be treatedwith intravenous
PIPs (5315 patients in year 2012). Directmedical costs for the next
5 years for PU was estimated at €78.5 million before the increased
pantoprazole prescription and at €77 million after its increase.
Mean cost per patient was estimated at 2,513€ before the in-
crease the pantoprazole participation and at 2464 after its
increase. CONCLUSIONS: This budget impact model estimates
that an increased intravenous pantoprazole prescription for the
treatment of PU in Spain is going to represent a net savings of €1.5
million in the Spanish Health Care System in the next ﬁve years.
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OBJECTIVES: To estimate the economic impact for the health
care system due to the substitution of intravenous omeprazole
and intravenous esomeprazole by intravenous pantoprazole in
the treatment of gastro oesophageal reﬂux disease in Spain.
METHODS: A budget impact model was developed. The ana-
lytic model was based on data from disease prevalence, popula-
tion growth, drug consumption, ex-factory prices and market
shares forecasts for Spain. It takes the perspective of the Spanish
National Health Care System and time horizon considered is ﬁve
years. Annual discount rate was set at 5%. Proton-pump inhibi-
tors (PPIs) are the drugs of choice for the treatment of gastro
oesophageal reﬂux disease (GERD) and drugs considered in the
study were omeprazole, esomeprazole and pantoprazole. The
model estimates the annual cost to treat patients with GERD
before and after the replacement by pantoprazol IV in the man-
agement of the disease in the Spanish setting. Annual costs
consist of pharmacologic treatments, laboratory and diagnostic
tests, specialist consultations, hospitalizations, transfusions,
endoscopic treatments and surgical interventions. All costs are
referred to 2007. RESULTS: It has been estimated that target
population with PPIs treatments for GERD in Spain would be
around 79,372 inhabitants in year 2007, arriving at 82,849 in
2012 due to Spanish population growth. Total cost for the next
5 years for the treatment of GERD with intravenous PIPs was
estimated at €1224 million before the substitution and at €1200
million after the substitution. Mean cost per patient was esti-
mated at €2513 before the replacement by intravenous panto-
prazole and at €2464 after its substitution. CONCLUSIONS:
This budget impact analysis estimates that increased pantopra-
zole intravenous prescription for the treatment of GERD in Spain
is likely to represent a net savings of €24 millions in the Spanish
National Health Care System in the next 5 years.
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OBJECTIVES: Alginates are often ﬁrst line therapy for patients
experiencing symptoms of gastro-oesophageal reﬂux (GORD).
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